Premedication With Labetalol Versus Metoprolol for Controlled Hypotension During Endoscopic Nasal Surgeries

• Status: Recruiting
• Trial end date: 2022-06-15
• Target enrollment: 0
• Participant gender: All

Summary

Background: Mucosal bleeding is the most frequent complication with endoscopic nasal surgeries, as it interferes with the optimal visualization of the intranasal anatomy, leading to increased risk of complications, increased operation time, and increased blood loss. There are several pharmacological techniques for the appropriate control of intraoperative bleeding.

Objectives: To compare the safety and efficacy of oral labetalol versus oral metoprolol as a premedication for controlled hypotensive anesthesia during endoscopic nasal surgeries.

Patients and Methods: This is a randomized, double-blind, phase four, comparative clinical trial; carried out on 60 patients, who were candidates for endoscopic nasal surgeries under general anesthesia at our hospital. Patients were randomly allocated into two equal groups; group L, received oral labetalol, and group M, received oral metoprolol.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Damanhour Teaching Hospital
• Treatments: Labetalol; Metoprolol

Criteria

Inclusion Criteria:

• American Society of Anesthesiologists (ASA) physical status ≤ II

• Age from 21 to 50 years

Exclusion Criteria:

• ASA physical status > II

• Age < 21 years or > 50 years

• Pregnant women

• Breastfeeding

• Bronchial asthma

• Chronic obstructive pulmonary disease

• Diabetes Mellitus

• Hypertension

• Ischemic heart disease

• Rheumatic heart disease

• Heart failure

• Heart block

• Sick sinus syndrome

• Sinus bradycardia

• Chronic hypotension

• Anemia (Hb < 10 g/dl)

• Renal or hepatic dysfunction

• Central nervous system disease

• Patients on beta-blockers

• Patients on calcium channel blockers

• Alcohol or drug abuse

• Anticoagulation therapy,

• Bleeding diathesis

• Agents influencing autonomic nervous system

• Allergy to the study drugs

• Any contraindication of oral intake